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Bariatric/metabolic surgery is considered an accepted treatment option for type 2 diabetes mellitus (T2DM) with body mass index
(BMI)  35kg/m2. Mounting evidence also shows that metabolic surgery is eﬀective for T2DM with BMI < 35kg/m2.T oe v a l u a t e
current status of metabolic surgery, we reviewed the available clinical studies which described surgical treatment for T2DM with
mean BMI < 35kg/m2. 18 studies with 477 patients were identiﬁed. 30% of the patients was insulin users. The follow-up period
ranged from 6 to 216 months. The weight loss eﬀect was reasonable, not excessive. Mean BMI decreased from 30.4 to 24.8kg/m2.
Remission of T2DM was achieved in 64.7% of the patients with fasting plasma glucose and glycated hemoglobin approaching
slightly above normal range. Clinical T2DM status was an important factor when selecting the eligible candidates for metabolic
surgery. Postoperative complication rate of 10.3% with mortality of 0% in the studies has been acceptable. Even though it would
be premature at this point to state that metabolic surgery is an accepted treatment option for T2DM with BMI< 35kg/m2,i ti s
clear that a high proportion of T2DM patients will derive substantial beneﬁt from metabolic surgery.
1.Introduction
Diabetes mellitus represents an expanding pandemic that
contributes markedly to worldwide morbidity and mortality.
The world prevalence of diabetes among adults (aged 20–
79 years) will be 6.4%, aﬀecting 285 million adults, in 2010
and will increase to 7.7% and 439 million adults by 2030 [1].
Thereisastrongrelationshipbetweenobesityandtype2dia-
betes mellitus (T2DM) [2]. In a large USA population study,
the prevalence of diabetes increases with increasing weight
classes according to body mass index (BMI). Approximately
half of those diagnosed with T2DM are obese [3]. Weight
control is the key to successful T2DM management. Weight
loss achieved by lifestyle interventions has been shown to be
eﬀective in preventing and treating T2DM [4–7]. However,
conventional treatment, such as, lifestyle modiﬁcation and
pharmacotherapy has produced small improvements in
weight [7–10]. By contrast, bariatric surgery has been shown
to eﬀectively provide durable weight loss [11].
Currently, bariatric surgery is now considered appro-
priate for T2DM patient with BMI  35kg/m2. Bariatric
surgery leads to remission of T2DM in the majority of
patients and improvement in the rest [12]. The American
Society of Bariatric and Metabolic surgery estimates that
the number of bariatric procedures increased from about
16,000 in the early 1990s to more than 103,000 in 2003 and
220,000 people in the United States had bariatric surgery
in 2008. Growing evidence from clinical and animal studies
indicates that bariatric/metabolic surgery may be beneﬁcial
for T2DM in nonseverely obese or even nonobese patients
(BMI < 35kg/m2)[ 13, 14]. Recently, International Diabetes
Federation has released its position statement [15]: surgery
should be an accepted option in people who have T2DM
a n dB M Io f3 5m o r e .S u r g e r ys h o u l db ec o n s i d e r e da sa n
alternative treatment option in persons with BMI 30 to 35
when diabetes cannot be adequately controlled by optimal
medical regimen, especially in the presence of other major
cardiovascular disease risk factors. The surgical approach is2 Journal of Obesity
now being extended to overweight and mild to moderate
obese (BMI < 35kg/m2) patients with T2DM.
Herein,toevaluatecurrentevidenceofmetabolicsurgery
for treatment of T2DM in patients with a BMI < 35kg/m2,
we conducted a review to date of available clinical studies.
2.MaterialsandMethods
2.1. Search Strategy and Study Inclusion Criteria. We con-
ducted a comprehensive review of all studies published con-
taining data on weight loss and T2DM-related outcomes of
patients treated with any form of bariatric/metabolic surgery
where the mean study BMI was <35kg/m2.O n l yr e p o r t s
published in English were included for review. Studies whose
inclusion criteria indicated bariatric or metabolic surgery
for low BMI patients were excluded if their mean BMI
was 35kg/m2, all participants were not T2DM patients,
diabetic participants had gastric surgery with anatomical
similarities to RYGB because of gastric cancer and ulcer, or
they did not report diabetes-related outcomes such as fasting
plasma glucose (FPG), glycated hemoglobin (HbA1c), and
postoperative clinical status. Pubmed was searched from
January 1, 1980, to November 1, 2011, for citations using the
following keywords: “metabolic surgery”, “bariatric surgery”,
“diabetes surgery”, “T2DM”, “type 2 diabetes”, “obesity”,
“BMI < 35kg/m2”, “mild to moderate obesity”, and “low-
BMI”. To supplement the electronic search, manual reference
checks were performed in the identiﬁed studies.
2.2. Data Reporting. Study authors, country, year of publica-
tion, surgical procedure, and study design were summarized.
Characteristics of the study groups, BMI, FPG, and HbA1c
were recorded. Diabetes-related clinical outcomes were col-
lected as % meds resolved (the percentage of the patients
who discontinued antidiabetic medication postoperatively)
and remission rate (the percentage of the patients who had
remissionorresolutionofT2DMaccordingtothevarieddef-
inition in the studies included). These two parameters were
calculated using available values if not speciﬁcally stated.
Then, the studies were divided into 2 groups according to
mean duration of T2DM prior to surgery. The percentage of
insulin using patients prior to surgery and T2DM remission
rate was compared. Regarding safety of metabolic surgery, all
major and minor complications were counted because they
were variably reported. Mortality was also checked.
2.3. Statistical Analysis. Weighted means for ages and dura-
tion of T2DM were calculated. Pre- and Postoperative mean
values (and corresponding 95% conﬁdence intervals) for
BMI, FPG, and HbA1c were summarized using a random
eﬀects model to account for the variability between the dif-
ferent studies. Only studies which provided both a pre- and
post-measurement were included in the mean estimation for
each of the parameters considered.
Comparisonsof2groupswithashort(<8years)andlong
history (>8 years) of diabetes with respect to insulin using
patients and diabetes remission were performed by the chi-
square test. The statistics was performed using the software
package PASW, version 18.0, for Windows (SAS Institute,
Cary, NC, USA).
3. Results
3.1. Study Characteristics. A total of 18 studies met inclusion
criteria as identiﬁed by literature search and reference checks
[16–33] Of the 18 studies, 17 (94%) were performed outside
of the United States, in Brazil (7, 39%), Italy (4, 22%),
Taiwan (4, 22%), Chile (1, 6%), and India (1, 6%). 13
studies (72%) have been published in the last 3 years from
2009 to 2011. The studies were performed prospectively
(16, 89%) or retrospectively (2, 11%). Surgical procedures
performed in this paper included Roux-en-Y gastric bypass
(RYGB) in 6 (33%) studies, duodenal-jejunal bypass (DJB)
in 4 (22%), biliopancreatic diversion (BPD) in 3 (17%),
minigastric bypass (MGB) in 2 (11%), ileal interposition
with sleeve or diverted sleeve gastrectomy (II-SG or II-DSG)
in 2 (11%), sleeve gastrectomy (SG) in 1 (6%), and stomach-
and pylorus-preserving BPD (BPD-SPP) in 1 (6%). The data
are summarized in Table 1.
3.2. Patient Characteristics. Of the 18 studies, total 477
patients underwent metabolic/bariatric surgery. 16 studies
reported the patient gender, and 53% of the total study
population was female. The mean age of the patients ranged
from 34 to 56 and its weighted mean was 47. The followup
period ranged from 6 months to 18 years, and its weighted
mean was 22 months. 2 studies reported the results of a
longer than 5-year followup. The duration of diabetes prior
tosurgeryrangedfrom6monthsto28years,anditsweighted
mean was 8.2 years. Majority of patients were taking oral
antidiabetic medication and/or insulin. The percentage of
Insulin using patients was 30.1% in 16 studies. The data are
summarized in Table 1.
3.3. BMI. 14 studies were included in the mean estimation.
The BMI decreased from 30.4 (95% CI 28.4–32.3) to 24.8
(95% CI 24.1–25.5) kg/m2. There were only two studies
reporting that one of the total 15 patients was in the mildly
undernourished range (BMI 17–18.5kg/m2)a f t e rR Y G B
without any evidence of malnutrition [21] and 12 patients
(17.4%) after II-DSG were underweight (BMI < 20kg/m2)
without lowering serum albumin value [24]. Overall, the risk
of excessive weight loss after metabolic surgery was 2.7% (13
patients). The data are summarized in Tables 2 and 3.
3.4. T2DM Outcomes. 12 studies were included in the mean
estimation of FPG. It decreased from 203.5 (95% CI 187.4–
219.6)to112.5(95%CI103.9–121.1)mg/dL.10studieswere
includedinthemeanestimationofHbA1c.Itdecreasedfrom
9.0 (95% CI 8.6–9.5) to 6.3 (95% CI 6.1–6.6) %. Regarding
clinical outcomes of diabetes, 86.8% of the patients stopped
taking antidiabetic medication after surgery (% meds oﬀ).
The deﬁnition of resolution or remission of T2DM varied.
When it is deﬁned as FPG < 126mg/dL and/or HbA1c <
6.5% without the use of antidiabetic medication at the time
ofevaluation,64.7%ofthepatientsmetthecriteria.Thedata
are summarized in Tables 2 and 3.Journal of Obesity 3
Table 1: Baseline characteristics of T2DM patients with BMI < 35kg/m2.
Author Year Procedure N Female/male Mean age
(range)
Mean followup
(range)
Mean
duration of
diabetes
Insulin user
1 Lee 2011 MGB, RYGB 62 38/24 43.1 24 months 5.4 years 23% (n = 14)
2 Boza 2011 RYGB 30 17/13 48.0 (28–65) 24 months
(n = 20) 4 years 3.3% (n = 1)
3 de Sa 2011 RYGB 27 — 50.3 20 (4–86) months 8.8 years 22% (n = 6)
4 Huang 2011 RYGB 22 20/2 47.4 (28–63) 12 months 6.6 years 18.2% (n = 4)
5 Scopinaro 2011 BPD 30 11/19 56.4 (43–69) 12 months 11.2 years 40% (n = 12)
6 Shah 2010 RYGB 15 7/8 45.6 9 months 8.7 years 80% (n = 12)
7 Lee 2010 SG 20 14/6 46.3 12 months >6 months 20% (n = 4)
8 DePaula 2009 II-SG, II-DSG 58 (30,28) 18/40 51.4 (40–66) 19.2 (14–28)
months 9.6 years 37.9% (n = 22)
9 DePaula 2009 II-DSG 69 22/47 51.4 (41–63) 21.7 (7–42)
months 11 years 44% (n = 30)
10 Ramos 2009 DJB 20 9/11 43.0 (29–60) 6 months 5.3 years 0% (n = 0)
11 Ferzli 2009 DJB 7 — 43.3 (33–52) 12 months 10.7 years 85.7% (n = 6)
12 Geloneze 2009 DJB 12 3/9 50.0 6 months 9 years 100% (n = 12)
13 Chiellini 2009 BPD 5 2/3 48.0 18 months 3–15 years —
14 Lee 2008 MGB 44 38/6 39.0 1–5 years — —
15 Scopinaro 2007 BPD 7 2/5 49.0 (39–60) 13 (10–18) years 4.1 years 0% (n = 0)
16 Cohen 2007 DJB 2 0/2 47.0 (43–51) 9 months 4.5 years 100% (n = 2)
17 Cohen 2006 RYGB 37 30/7 34.0 (28–45) 20 (6–48) months — 0% (n = 0)
18 Noya 1998 BPD-SPP 10 5/5 52.1 (40–62) 7 (2–18) months — 40% (n = 4)
Total — — 477 236/207 — — — 30.1%
(129/428)
Weighted
mean — — — — 47 22 months 8.2 years —
RYGB: Roux-en-Y gastric bypass, MGB: mini-gastric bypass, BPD: biliopancreatic diversion, SG: sleeve gastrectomy, II-SG: ileal interposition with sleeve
gastrectomy, II-DSG: ileal interposition with diverted sleeve gastrectomy, DJB: duodenal jejunal bypass, BPD-SPP: stomach- and pylorus-preserving BPD.
3.5. Clinical Outcomes of Diabetes According to Duration of
T2DM prior to Surgery. When the studies were stratiﬁed by
mean duration of T2DM (5 studies, 8 years, and 7 studies,
>8 years), the percentage of insulin-using patients prior to
surgery was 18.2% and 45.9% (P<0.01). Remission of
T2DM was achieved in 66.0% of the patients with a short
history (8 years) of T2DM and 52.9% of those with a long
history (>8y e a r s )o fT 2 D M( P = 0.03). The data are shown
in Figure 1.
3.6. Complications and Mortality. Overall, complication rate
was 10.3% (range 4.5–33.3%) in 16 studies. The types
of complication varied and were dependent on follow-up
period and surgical procedures. Therefore, we included all
major and minor complications. The mortality rate was 0%
in 17 studies. The data are summarized in Table 2.
4. Discussion
The concept of metabolic surgery was deﬁned by Buchwald
and Varco in 1978 in their book “Metabolic Surgery as the
operative manipulation of a normal organ or organ system
to achieve a biological result for a potential health gain”
[34]. Now, metabolic surgery is deﬁned as any modiﬁcation
of the gastrointestinal (GI) tract, where rerouting the food
passage seems to improve T2DM, based on mechanisms
that are weight loss independent. This new frontier of
bariatric/metabolic surgery includes the application of con-
ventional bariatric procedures (RYGB, BPD, SG, MGB)
and the introduction of new procedures (DJB, II-SG, II-
DSG, BPD-SPP) designed with the speciﬁc aim of having
metabolic eﬀects irrespective of causing massive weight loss.
There is strong evidence that bariatric surgery for
severely obese patients (BMI  35kg/m2)p r o v i d e se x c e p -
tional sustained weight loss and 50–85% remission of
T2DM [35]. In view of growing enthusiasm for surgical
interventionstotreatT2DM,the1stdiabetessurgerysummit
was held in Rome in March 2007 to develop guidelines for
the use of GI surgery to treat T2DM. The recommendations
were made by a multidisciplinary group of 50 voting
delegates [36]. Accordingly, the “Standards of Medical Care
in Diabetes” published yearly by the American Diabetes
Association, for the ﬁrst time, mentions surgical therapy
in 2009 [37]. Recently, International Diabetes Federation
has released its position statement [20]. These statements4 Journal of Obesity
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Table 3: Mean estimation of BMI, FPG, and HbA1c before and after metabolic surgery. Combined data from 18 existing bariatric studies.
Variable (# studies) Pre Means ± SE 95% CI Post Means ± SE 95% CI
BMI (n = 14), kg/m2 30.4 ±0.98 (28.4, 32.3) 24.8 ±0.33 (24.1, 25.5)
FPG (n = 12), mg/dL 203.5 ±8.2 (187.4, 219.6) 112.5 ±4.4 (103.9, 121.1)
HbA1c (n = 10), % 9.01 ±0.22 (8.6, 9.5) 6.3 ±0.14 (6.1, 6.6)
SE: standard error.
have mentioned that bariatric surgery for T2DM patients
with a BMI  35kg/m2 is considered an accepted option as
with standard medical therapy and metabolic surgery might,
moreover, be considered a reasonable therapeutic alternative
for low BMI (<35kg/m2) patients with T2DM who do not
respond to standard medical therapy. The aim of this paper
was to explore the current evidence with a view to evaluate
the potential of metabolic surgery for T2DM with a BMI <
35kg/m2.
Metabolic surgery to treat T2DM in patients with low
BMI provided desirable results regarding weight loss. The
e s t i m a t e dm e a nB M Ic a t e g o r i z e da sc l a s sIo b e s i t yp r i o r
to surgery reached normal weight range after surgery.
Importantly, only 13 patients (2.7%) following RYGB or II-
DSG in 2 studies reported excessive weight loss, and they
did not show any evidence of malnutrition [21, 24]. Even
the procedures that typically produce the greatest reduction
in BMI and excess weight in morbidly obese patients did
not aﬀect a similarly dramatic BMI reduction in the low-
BMI patients [38]. Scopinaro and so forth reported that BPD
does not entail risk of excessive or undue weight loss because
there is a maximum energy absorption capacity after the
operation, which corresponds to a weight of stabilization of
low BMI patients [39]. The similar homeostatic mechanism
mayexplainweightstabilizationwithoutcausingundesirable
weight loss after surgical procedures including intestinal
bypass.
In this paper, diabetic status was signiﬁcantly improved
after metabolic surgery in the majority of studies. Dis-
continuation of antidiabetic medication and remission of
T2DM after metabolic surgery were achieved in 86.8% and
64.7% of the patients with FPG and HbA1c approaching
slightly above normal range. Moreover, metabolic surgery
provided adequate glycemic control for 30.1% of the patients
using insulin prior to surgery. It has been described that
malabsorptive bariatric procedures have higher diabetes
remissionratesthanrestrictiveones[12,40].T2DMtypically
resolves within a few days to weeks following malabsorptive
procedures such as RYGB and BPD before signiﬁcant weight
loss is achieved. Although the exact mechanism is not yet
fully understood, growing evidence shows that malabsorp-
tive procedures involving rerouting of food might improve
T2DM by enhancing insulin sensitivity and/or by improving
β-cell function that is additive to weight loss and reduced
caloric intake [16, 41, 42] .T h er e c e n ts t u d i e sh a v ed e s c r i b e d
that acute insulin response to intravenous glucose and
early phase insulin response to oral glucose load improved
signiﬁcantly within a month following GI bypass surgery
[16, 20]. The mechanism for these changes could be due to
a dramatic decrease of insulin resistance and an increase in
0
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Figure 1: Clinical outcomes of diabetes according to duration of
T2DM prior to surgery. ∗∗P<0.01, ∗P<0.05.
postprandial plasma levels of glucagon-like peptide-1 (GLP-
1) early after surgery. Currently, two hypotheses (hindgut
and foregut theory) have been proposed to explain T2DM
remission after metabolic surgery in addition to decreased
calorie intake after surgery and surgical-induced weight loss
which might contribute to improving insulin sensitivity. The
former states that surgical rerouting of nutrients to the distal
part of the small intestine results in increased secretion
and concomitant glucose-lowering eﬀects of GLP-1, and
the latter emphasizes that surgical bypass of the foregut
prevents the release of a hitherto unidentiﬁed nutrient-
induced diabetogenic signal in susceptible individuals [43].
The novel surgical procedures such as DJB, BPD-SPP, II-SG,
and II-DG were designed to apply hindgut or/and foregut
hypotheses without massive weight loss and achieved 56% of
T2DM remission and 84% of diabetes meds oﬀ in this paper.
The weight loss eﬀect of metabolic surgery on T2DM in low
BMIpatientsmightbelowerthanthatofbariatricsurgeryon
T2DM in high BMI patients. Understanding and enhancing
the abovementioned mechanism are the key to success in
metabolic surgery.
There is no strong evidence describing the durability of
metabolic surgery in long-term followup. In this paper, 2
studies showed durable diabetes remission of T2DM during
5–18 years period after MGB and BPD [29, 30]. By contrast,
therecentstudiesofbariatricsurgeryforT2DMpatientswithJournal of Obesity 7
severeobesityshowedthat24%–43%ofthepatientswithini-
tial remission or improvement of their T2DM subsequently
developed T2DM recurrence or worsening during the mid-
to long-term followup period [44, 45]. A low preoperative
BMI and severe T2DM status were associated with failure
of consistent durable remission of diabetes. The common
causes for failure of diabetes remission after bariatric surgery
are known as inadequate weight loss or regain of weight,
longstanding poorly controlled or aggressive T2DM, lower
preoperative BMI, and latent autoimmune diabetes in adults
(LADA) [46]. LADA comprises 10% of diabetic age 30–55
and is more prevalent in low BMI individuals [47, 48].
Mostclinicalguidelinesandstatementshavefollowedthe
BMI-based criteria established by 1991 National Institutes
of Health Consensus Conference Guidelines [49]. Although
BMI is convenient to classify the grade of obesity, it does
not seem to be appropriate in selecting the suitable T2DM
candidates for metabolic surgery. For instance, the risk
of diabetes and/or metabolic syndrome is determined by
ethnicity, waist circumference,fat distribution, body compo-
sition,andintrahepaticfat[50,51].SouthAsianandChinese
individuals have distributions of elevated glucose and lipid
levels similar to Europeans at signiﬁcantly lower BMI values
[52]. The natural history of type 2 diabetes is also important
to consider in determining the timing of intervention. As
the diabetes state progresses, there is continued beta-cell
deterioration together with a decline in insulin secretion
within 6–10 years of T2DM diagnosis [53, 54]. Schauer et al.
showed that a shorter history of diabetes and milder disease
according to preoperative medication status were associated
with an increased likelihood of remission after RYGB [55].
DixonandO’Brienreportedthatashorterhistoryofdiabetes
and greater weight loss were positive predictive factors for
remission[56].Thispaperwasconsistentwiththis.Ashorter
history of diabetes with less number of insulin using patients
prior to metabolic surgery resulted in greater remission rate
of diabetes. Metabolic surgery should be considered early in
the diabetic stage before irreparable beta-cell damage occurs.
BMI alone is not an adequate measure to deﬁne the overall
risk of morbidity and mortality in patients with established
diabetes [50]. The clinical status of T2DM should be taken
into account to select the suitable candidates for metabolic
surgery.
The goals of treatment of T2DM are not only glycemic
controlbutalsopreventionofdiabetes-relatedcomplications
such as macro- and microvascular diseases. The target blood
pressure of <130/80mmHg, the target cholesterol level of
<200mg/dL, and HbA1C level <7% should be achieved
in diabetic patients. It has been reported that only 7.3%
of adults with diabetes achieved all three recommended
goals with conventional medical treatment [57]. In contrast,
bariatric surgery improved hyperlipidemia in 70% or more
o fp a t i e n t sa n dr e s o l v e do ri m p r o v e dh y p e r t e n s i o ni n
78.5% of patients [58]. A systematic review to evaluate
the eﬀect of bariatric surgery on cardiovascular risk proﬁle
demonstrated that on average, hypertension, diabetes, and
dyslipidemia resolved in 68%, 75%, and 71% and a 40%
relative risk reduction for 10-year coronary heart disease
risk was observed after bariatric surgery, as determined by
the Framingham risk score [59]. In this paper, Shah et
al. reported that RYGB for T2DM in low BMI patients
reduced the predicted 10-year cardiovascular disease risk
substantially for fatal and nonfatal coronary heart disease
and stroke [21].
The mortality rates from bariatric operations (0.28–
0.35%) [60] are compared favorably with those of other
commonly performed operations, including laparoscopic
cholecystectomy, whose mortality in USA ranges between
0.35 and 0.60% [61]. In this paper, no mortality was
observed. Major and minor complication rate was also
low (10.3%). Huang et al., and so forth reported that the
operating time and duration of hospitalization of LRYGB
for low BMI patients were lower than those for morbidly
obese patients because of lower BMI [19]. T2DM-related
additional risk should be counted, but safety of metabolic
surgery for low BMI patients seems to be higher or at least
similar, compared to bariatric surgery for severe obesity.
Metabolic surgery for T2DM, although not the current
standard care for the disease, may be coming closer to
the mainstream. The ponderable statement has suggested
that metabolic surgery might be considered a reasonable
therapeutic alternative for low BMI (<35kg/m2) patients
with T2DM who do not respond to standard medical
therapy. The data from the studies included in this paper
are encouraging. Although large randomized clinical trials
against best medical care and assessment of the long-term
eﬃcacy and safety should be prioritized to deﬁne the role of
metabolic surgery, it is clear that a high proportion of low
BMI patients with T2DM will derive substantial beneﬁt from
metabolic surgery.
5. Conclusions
In this paper, including 18 studies and 477 patients, T2DM
patients with a BMI < 35kg/m2 derived beneﬁt from
metabolic surgery. The weight loss eﬀect was reasonable
without any serious excessive weight loss. The antidiabetic
eﬀect was also considered excellent. Remission of T2DM
and % meds oﬀ were achieved in 64.7% and 86.8% of
the patients. T2DM clinical status is important to select
the eligible candidates for metabolic surgery besides current
BMI criteria for bariatric surgery. Metabolic surgery can be
performed safely with acceptably low complication rate and
mortality. Although several concerns need to be addressed,
metabolic surgery for low BMI patients is coming closer to
the mainstream of diabetes treatment.
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